Home › NDC Lookup › Ingredients › Guaifenesin And Pseudoephedrine Hcl › 55111-0799-36
Guaifenesin and Pseudoephedrine HCL 1200 mg; 120 mg Tablet, Extended Release — NDC 55111-0799-36 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Guaifenesin and Pseudoephedrine HCL 1200 mg; 120 mg Tablet, Extended Release — NDC 55111-799-36 (Billing 55111-0799-36)

by Dr. Reddy's Laboratories Limited · 3 BLISTER PACK in 1 CARTON / 12 TABLET, EXTENDED RELEASE in 1 BLISTER PACK

This is a package of Guaifenesin and Pseudoephedrine HCL 1200 mg; 120 mg Tablet, Extended Release from Dr. Reddy's Laboratories Limited, marketed since Dec 2017 and currently FDA-listed.

NDC 55111-0799-36
🏷️ FDA NDC (as labeled) 55111-799-36 billing pads the product segment with a zero
This package
Contains12 tablet, extended release in 1 blister pack Pack sizes5 compare ↓
Product page 55111-0799-24 Also comes in: 6 tablets 55111-799-04 12 tablets 55111-799-12 12 tablets 55111-799-24 12 tablets 55111-799-84
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 2, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 55111-799-36
Product NDC 55111-799
11-digit billing NDC 55111079936
SPL Set ID 845a2dcc-9069-3141-ae13-f2063f36d130
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2017-12-29
Dosage form TABLET, EXTENDED RELEASE
Substance GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 43996202307492
GPI class Pseudoephedrine-guaiFENesin ER
GCN Seq No 045917
GCN 89731
HICL code 000270
Ingredient (HICL) Guaifenesin/Pseudoephedrne Hcl
HIC1 code B
Therapeutic class — broad (HIC1) Respiratory System
HIC2 code B4
Therapeutic class — intermediate (HIC2) Drugs Affecting The Trachea And Bronchi (Contin.1)
HIC3 code B4W
Therapeutic class — specific (HIC3) Decongestant-Expectorant Combinations
AHFS code 12:12.12.00
AHFS class Alpha- And Beta-Adrenergic Agonists
FDB label name GUAIFENESIN-PSE ER 1200-120 MG
FDB brand name Guaifenesin-Pseudoephedrine Er
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 045917
  • GCN: 89731
  • GPI-14 (Medi-Span): 43996202307492
  • HICL (First Databank): 000270
  • AHFS class code: 12:12.12.00
Why two NDCs? The FDA registers this code as 55111-799-36 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 55111-0799-36. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name GUAIFENESIN-PSE ER 1200-120 MG Ingredient Guaifenesin/Pseudoephedrne Hcl
📗 Our plain-language guide HelloPharmacist
  • It helps loosen chest mucus so your cough is more productive. It also temporarily relieves nasal and sinus congestion from a cold, hay fever or other upper respiratory allergies.
  • Swallow them whole with a full glass of water. Don't crush, chew or break them. You can take them with or without food, and they're usually taken about every 12 hours. Follow the p...
  • How should I take the extended-release tablets?
  • Be careful here. If your medicine is an MAOI, you shouldn't take this product, or for 2 weeks after stopping the MAOI. If you aren't sure what your prescription is, ask me before y...
📖 Read our full Guaifenesin / Pseudoephedrine guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 6 tablets 12 tablets 12 tablets 12 tablets
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
55111-0799-04 55111-799-04 4 BLISTER PACK in 1 CARTON / 6 TABLET, EXTENDED RELEASE in 1 BLISTER PACK — — 2017-12-29 — Active
55111-0799-12 55111-799-12 1 BLISTER PACK in 1 CARTON / 12 TABLET, EXTENDED RELEASE in 1 BLISTER PACK — — 2017-12-29 — Active
55111-0799-24 55111-799-24 Main listing 2 BLISTER PACK in 1 CARTON / 12 TABLET, EXTENDED RELEASE in 1 BLISTER PACK $0.4235 / ea $10.16 2017-12-29 — Active
55111-0799-36 You're viewing this 3 BLISTER PACK in 1 CARTON / 12 TABLET, EXTENDED RELEASE in 1 BLISTER PACK — — 2017-12-29 — Active
55111-0799-84 55111-799-84 5 BLISTER PACK in 1 CARTON / 12 TABLET, EXTENDED RELEASE in 1 BLISTER PACK — — — — Active

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 3 blister pack in 1 carton / 12 tablet, extended release in 1 blister pack.
What NDC number is used to bill for this package of Guaifenesin and Pseudoephedrine HCL 1200 mg; 120 mg Tablet, Extended Release?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Mucus D 1200 mg/1; 120 mg 00113-8911-62 L. 6 tablets $0.423 — Availability likely —
Leader Mucus Relief D 1200 mg/1; 120 mg 70000-0719-01 Cardinal 6 tablets $0.423 — Availability likely —
foster and thrive mucus relief d 1200 mg/1; 120 mg 70677-1273-01 Strategic 6 tablets $0.423 — Availability likely —
Mucinex D Maximum Strength 1200 mg/1; 120 mg 63824-0041-12 Reckitt 12 tablets $0.979 — Discontinued —
Guaifenesin and Pseudoephedrine HCl 1200 mg/1; 120 mg 00363-0134-78 WALGREEN 12 tablets — — FDA listed —
mucus relief d 1200 mg/1; 120 mg 00363-2389-62 Walgreen 6 tablets — — FDA listed —
Mucus Relief D 1200 mg/1; 120 mg 00363-7064-24 Walgreens 6 tablets — — FDA listed —
Mucus Relief D 1200 mg/1; 120 mg 11822-7399-04 Rite 6 tablets — — FDA listed —
Mucus Relief D 1200 mg/1; 120 mg 49035-0261-12 Wal-mart 12 tablets — — FDA listed —
mucus d 1200 mg/1; 120 mg 51316-0345-62 CVS 6 tablets — — FDA listed —
MAXIMUM STRENGTH Mucus D 1200 mg/1; 120 mg 51316-0970-24 CVS 24 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine HCl 1200 mg/1; 120 mg 51660-0077-12 Ohm 12 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine HCL 1200 mg/1; 120 mgthis 55111-0799-36 Dr. 12 tablets — — FDA listed —
nasal and chest decongestant 1200 mg/1; 120 mg 56062-0614-62 Publix 6 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine HCl 1200 mg/1; 120 mg 58602-0834-77 Aurohealth 12 tablets — — FDA listed —
mucus relief d 1200 mg/1; 120 mg 59640-0300-62 H 6 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine HCl 1200 mg/1; 120 mg 62207-0828-71 Granules 10 tablets — — FDA listed —
Mucus Relief D 1200 mg/1; 120 mg 69842-0211-24 CVS 6 tablets — — FDA listed —
mucus D 1200 mg/1; 120 mg 79481-0119-00 Meijer, 3 tablets — — FDA listed —
Equate Mucus D 1200 mg/1; 120 mg 79903-0388-24 WALMART 6 tablets — — FDA listed —
Guaifenesin and Pseudoephedrine HCl 1200 mg/1; 120 mg 59651-0288-11 Aurobindo 1000 tablets — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2017
On the market since
Dec 2017
📍
2026
Currently FDA-listed
9 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color Orange
ShapeCapsule
ImprintRDY;799
Size22 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII H77VEI93A8
    A synthetic yellow dye used to color medications. It helps identify the drug and make it visually distinctive, with no effect on how the medicine works.
  • UNII 3NXW29V3WO
    Hypromellose is a plant-based thickener made from cellulose. It's used in medicines as a binder to hold ingredients together, a coating for tablets, and a thickener for liquids.
  • UNII EWQ57Q8I5X
    Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII FZ989GH94E
    Povidone is a synthetic polymer made from a plastic-like material. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in your stomach so the medicine can be absorbed.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.

7 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statesFD & C yellow #6, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, silicon dioxide.

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerDr. Reddy's Laboratories Limited
Labeler code55111
First marketedDec 2017
Product typeDrug For Further Processing
Portfolio200 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 Ask a Doctor Before Use If 📄 When Using This Product 📄 Stop Use and Ask a Doctor If 🤰 If Pregnant or Breast-Feeding 📄 Keep Out of Reach of Children 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 62 words ▾

Use(s) ■ helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bother some mucus and make coughs more productive ■ temporarily relieves nasal congestion due to: ■ common cold ■ hay fever ■ upper respiratory allergies ■ temporarily restores freer breathing through the nose ■ promotes nasal and/or sinus drainage ■ temporarily relieves sinus congestion and pressure

⏱️ Dosage and Administration 94 words ▾

Directions ■ do not crush, chew, or break extended-release tablet ■ take with a full glass of water ■ this product can be administered without regard for timing of meals ■ children under 12 years of age: do not use For 600 mg/60 mg ■ adults and children 12 years and older: 2 extended-release tablets every 12 hours; not more than 4 extended-release tablets in 24 hours For 1200 mg/120 mg ■ adults and children 12 years and older: 1 extended-release tablet every 12 hours; not more than 2 extended-release tablets in 24 hours

⚠️ Warnings 187 words ▾

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product. Ask a doctor before use if ■ heart disease ■ high blood pressure ■ thyroid disease ■ diabetes ■ trouble urinating due to an enlarged prostate gland ■ persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema ■ cough accompanied by too much phlegm (mucus) When using this product ■ do not use more than directed Stop use and ask doctor if ■ you get nervous, dizzy, or sleepless ■ symptoms do not get better within 7 days, come back or occur with a fever, rash, or persistent headache.

These could be signs of a serious illness. Pregnancy/Breastfeeding ask a health professional before use. Keep out of reach of children In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

📦 Storage and Handling 6 words ▾

Storage ■ store between 20°-25°C (68°-77°F)

🧪 Active Ingredient 22 words ▾

Active ingredient(s) Guaifenesin USP, 600 mg................................................................................Expectorant Pseudoephedrine HCl USP, 60 mg......................................................Nasal Decongestant Guaifenesin USP, 1200 mg................................................................................Expectorant Pseudoephedrine HCl USP, 120 mg......................................................Nasal Decongestant

🧪 Inactive Ingredients 17 words ▾

Inactive ingredients FD & C yellow #6, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, silicon dioxide.

🎯 Purpose 5 words ▾

Purpose Expectorant and Nasal Decongestant

📄 Do Not Use 55 words ▾

Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.

📄 Ask a Doctor Before Use If 50 words ▾

Ask a doctor before use if ■ heart disease ■ high blood pressure ■ thyroid disease ■ diabetes ■ trouble urinating due to an enlarged prostate gland ■ persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema ■ cough accompanied by too much phlegm (mucus)

📄 When Using This Product 11 words ▾

When using this product ■ do not use more than directed

📄 Stop Use and Ask a Doctor If 41 words ▾

Stop use and ask doctor if ■ you get nervous, dizzy, or sleepless ■ symptoms do not get better within 7 days, come back or occur with a fever, rash, or persistent headache. These could be signs of a serious illness.

🤰 If Pregnant or Breast-Feeding 7 words ▾

Pregnancy/Breastfeeding ask a health professional before use.

📄 Keep Out of Reach of Children 22 words ▾

Keep out of reach of children In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

📄 Questions or Comments 39 words ▾

Questions call 1-888-375-3784 You may also report side effect to this phone number. Keep the carton. It contains important information. See end panel for expiration date. DISTRIBUTED BY: Dr. Reddy’s Laboratories Inc., Princeton, NJ – 08540 Made in India

📄 Package Label / Principal Display Panel 25 words ▾

Principal Display Panel Guaifenesin and Pseudoephedrine HCl ER Tablets 600 mg/60 mg: 18s (1x18s)

Guaifenesin and Pseudoephedrine HCl ER Tablets 1200 mg/120 mg: 24s (2x12s)

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Guaifenesin and Pseudoephedrine HCl — the ingredient across all brands.

Top reported reactions

Emotional Distress3
Pain3
Abdominal Pain Upper2
Anxiety2
Asthma2
Dyspnoea2
Fatigue2

Age at onset

Adult4
Elderly1

Reporter sex

20 reports
Male · 35%
Female · 65%

Serious outcomes

Hospitalization5
Disabling2
Reports over time (by year) — tap or hover for the count & year
2020 2022 2024 2026 5 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Dr. Reddy's Laboratories Limited supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Dr. Reddy's Laboratories Limited. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 4 other package presentations of this same product, including 6 tablets (55111-0799-04), 12 tablets (55111-0799-12), 12 tablets (55111-0799-24). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Dr. Reddy's Laboratories Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 55111-0798-09 · Dr. 55111-0800-00 · Dr.Reddy's →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.